Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is a leading global pharmaceutical company with a strong focus on prescription drugs and vaccines, which account for the majority of their sales. Their strong presence in emerging markets and successful products such as Prevnar 13 and Eliquis contribute to their positive outlook. Upcoming data readouts in oncology and obesity, as well as potential NPV accretion from their pivotal tafamidis bench trial, could provide upside for the stock. However, risks include significant patent expirations in 2026-2028 and potential challenges to their key patents. Overall, Pfizer's proactive capital deployment and growth initiatives balance out these risks and support their current valuation.

Bears say

Pfizer is facing a number of headwinds that could negatively impact its stock. First, the company has significant exposure to emerging markets, which may be more volatile and present challenges with issues like access to medicines and regulatory hurdles. Additionally, Pfizer has a high concentration of upcoming patent expirations, leading to a potential earnings trough in 2028-2029. Furthermore, the company's recent track record in M&A has been mixed, creating uncertainty around its ability to drive growth through acquisitions. Overall, these factors contribute to a negative outlook for Pfizer's stock.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.